Form Type: 4

SEC EDGAR Link
Accession Number:0000914190-20-000182
Date:2020-05-21
Issuer: BIO-TECHNE CORP (TECH)
Original Submission Date:

Reporting Person:

BAUMGARTNER ROBERT V
5775 WAYZATA BOULEVARD, SUITE 400
MINNEAPOLIS, MN 55416

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-05-21 M 5,000 a $70.35 14,221 direct
COMMON STOCK 2020-05-21 S 1,300 d $265.35 12,921 direct
COMMON STOCK 2020-05-21 S 1,601 d $266.07 11,320 direct
COMMON STOCK 2020-05-21 S 1,974 d $267.32 9,346 direct
COMMON STOCK 2020-05-21 S 125 d $267.94 9,221 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTIONS (RIGHT TO BUY) 70.35 2020-05-21 deemed execution date M 5,000 (d) 2011-10-27 2021-10-26 common stock 5,000 $70.35 0 direct
STOCK OPTIONS (RIGHT TO BUY) 66.9 2020-05-21 deemed execution date 0 ( ) 2012-10-25 2022-10-24 common stock 5,000 $66.90 5,000 direct
STOCK OPTIONS (RIGHT TO BUY) 87.39 2020-05-21 deemed execution date 0 ( ) 2013-10-31 2023-10-30 common stock 4,000 $87.39 4,000 direct
STOCK OPTIONS (RIGHT TO BUY) 91.78 2020-05-21 deemed execution date 0 ( ) 2014-10-30 2024-10-30 common stock 4,000 $91.78 4,000 direct
STOCK OPTIONS (RIGHT TO BUY) 87.34 2020-05-21 deemed execution date 0 ( ) 2016-10-29 2025-10-28 common stock 4,260 $87.34 4,260 direct
STOCK OPTIONS (RIGHT TO BUY) 101.19 2020-05-21 deemed execution date 0 ( ) 2017-10-26 2026-10-26 common stock 3,985 $101.19 3,985 direct
STOCK OPTIONS (RIGHT TO BUY) 125.05 2020-05-21 deemed execution date 0 ( ) 2018-10-25 2027-10-26 common stock 3,125 $125.05 3,125 direct
STOCK OPTIONS (RIGHT TO BUY) 179.84 2020-05-21 deemed execution date 0 ( ) 2019-10-24 2028-10-25 common stock 1,898 $179.84 1,898 direct
STOCK OPTIONS (RIGHT TO BUY) 201.64 2020-05-21 deemed execution date 0 ( ) 2029-10-24 common stock 2,011 $201.64 2,011 direct
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f5 the option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of bio-techne's 2020 annual meeting of shareholders.
WhaleWisdom Logo

Elevate your investments